Cladribine induces immunophenotypical changes in bone marrow mast cells from mastocytosis
- 1 November 2002
- journal article
- case report
- Published by Elsevier in Leukemia Research
- Vol. 26 (11) , 1043-1046
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosisLeukemia Research, 2001
- Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findingsLeukemia Research, 2001
- Diagnostic criteria and classification of mastocytosis: a consensus proposalLeukemia Research, 2001
- Treatment of Systemic Mast-Cell Disease with CladribineNew England Journal of Medicine, 2001
- Clinical and Biologic Diversity of Leukemias Occurring in Patients with MastocytosisLeukemia & Lymphoma, 2000
- Immunophenotypic Characterization of Human Bone Marrow Mast Cells. A Flow Cytometric Study of Normal and Pathological Bone Marrow SamplesAnalytical Cellular Pathology, 1998
- Systemic Mast Cell Disease Associated with Hairy Cell LeukaemiaLeukemia & Lymphoma, 1997
- Cladribine (2-chloro-deoxyadenosine, CDA): an inhibitor of human B and T cell activation in vitroImmunopharmacology, 1993
- A case of POEMS syndrome associated with essential thrombocythaemia and dermal mastocytosisPostgraduate Medical Journal, 1990
- Hematologic malignancies occurring in patients with urticaria pigmentosaJournal of the American Academy of Dermatology, 1982